From dismal prognosis to rising star: melanoma leads the way with new generation cancer therapies
Author:
Affiliation:
1. Melanoma Institute Australia, Sydney, NSW.
2. University of Sydney, Sydney, NSW.
3. Mater Hospital, Sydney, NSW.
Publisher
Wiley
Subject
General Medicine
Link
https://onlinelibrary.wiley.com/doi/pdf/10.5694/mja14.01718
Reference25 articles.
1. Final Version of 2009 AJCC Melanoma Staging and Classification
2. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
3. Nivolumab plus Ipilimumab in Advanced Melanoma
4. Updated overall survival (OS) for BRF113220, a phase 1‐2 study of dabrafenib (D) alone versus combined dabrafenib and trametinib (D+T) in pts with BRAF V600 mutation‐positive (+) metastatic melanoma (MM) [abstract]. 2014 ASCO Annual Meeting;Flaherty K;J Clin Oncol,2014
5. RobertC LongGV BradyB et al.Nivolumab in previously untreated melanoma withoutBRAFmutation.N Engl J Med2014; 16 Nov [Epub ahead of print].
Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. An outreach telephone program for advanced melanoma supportive care: Acceptability and feasibility;European Journal of Oncology Nursing;2019-10
2. A real world example of coverage with evidence development in Australia - ipilimumab for the treatment of metastatic melanoma;Journal of Pharmaceutical Policy and Practice;2018-02-13
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3